TMC launches cancer-focused partnership with Japan

global collaboration

The partnership between Japan-based Mitsui Fudosan Co. Ltd. and the National Cancer Center will focus on advancing cancer treatments, providing a pathway for Japanese innovators to expand in the U.S. market. Photo courtesy of TMC

Houston's Texas Medical Center announced the launch of its new TMC Japan BioBridge and Japan-Accelerator Cancer Therapeutics and Medical Devices, or JACT, this month.

The strategic partnership between Japan-based Mitsui Fudosan Co. Ltd. and the National Cancer Center will focus on advancing cancer treatments and providing a pathway for Japanese innovators to expand in the U.S. market. A delegation from TMC recently visited Tokyo, and William F. McKeon, president and CEO of TMC, signed the TMC Japan BioBridge Memorandum of Understanding with Takeshi Ozane, general manager of Mitsui Fudosan, and Hitoshi Nakagama, president of the National Cancer Center of Japan.

“The launch of TMC Japan BioBridge is a vital step forward in connecting two global leaders in healthcare innovation,” McKeon says in a statement. “Japan’s leadership has demonstrated an impressive commitment to advance medical cures and life sciences technologies and through this partnership, we are opening necessary doors for Japanese researchers and innovators to access the US market and collaborate with our TMC ecosystem. Together, we aim to accelerate critical breakthroughs to make a difference for patients all around the world.”

The new JACT will offer cancer-treatment companies a structured process to prepare for a U.S. expansion and will allow for meetings with pharmaceutical companies, hospital systems and investors and provide insights on U.S. regulatory approvals. It'll focus on three key areas, according to the statement:

  1. Milestone development and financial planning
  2. Clinical and regulatory expertise
  3. Strategic partnerships and market insights

“This TMC Japan BioBridge and JACT Program will enable us to promote the advancement of start-up companies aiming to commercialize innovative medical technologies originating in Japan into the U.S." Nakagama says in a statement. "We also hope this collaboration will not be limited to our (Japan Agency for Medical Research and Development)-supported project, but will lead to further cooperation between TMC, NCC, and other Japanese institutions in various fields.”

This is the sixth international strategic partnership for the TMC. It launched its first BioBridge, which focus on partnerships to support international healthcare companies preparing for U.S. expansion, with the Health Informatics Society of Australia in 2016. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.

From Your Site Articles
The University of Houston and Heriot-Watt University in Scotland have secured funding for six energy projects. Photo via UH.edu

University of Houston taps global partner to work on hydrogen, sustainability breakthroughs

team work

The University of Houston and Scotland’s Heriot-Watt University have been awarded seed grants to six energy projects, which is part of an innovative transatlantic research collaboration.

Researchers from both universities will take on projects that will concentrate on innovations that range from advanced hydrogen sensing technology to converting waste into sustainable products.

This will mark the first round of awards under the “UH2HWU” seed grant program. The program was created following the signing of a memorandum of understanding between both institutions in 2024. The universities will “seek to drive global progress in energy research, education, and innovation, with a particular focus on hydrogen as a key element in the shift toward cleaner energy,” according to a news release.

“This partnership is rooted in a shared commitment to advancing research that supports a just energy transition,” Ramanan Krishnamoorti, vice president for energy and innovation at UH, says in a news release. “Hydrogen, and in particular low carbon hydrogen, is essential to achieving sustainable energy solutions.”

The UH2HWU program provided $20,000 in seed funding to each of the projects. The program will help with the goal of helping researchers secure additional funding from private sources, companies, and government with a total of 11 proposals being submitted, and a panel of industry experts reviewing them.

One of the winning projects was titled “A joint research project on the feasibility of Repurposing Offshore Infrastructure for Clean Energy in the North Sea aka ROICE North Sea,” and was led by Ram Seetharam, ROICE Program executive director at UH, Edward Owens, professor of energy, geoscience, infrastructure and society at HWU, and Sandy Kerr, associate professor of economics at HWU.

The UH ROICE team focused on reusing old offshore structures for clean energy instead of removing them after their productive life. The UH team created cost and project models for the Gulf of Mexico and will now work with Heriot-Watt University to apply to UK North Sea. UK North Sea has over 250 platforms and about 50,000 kilometers of pipelines. To see more of the projects click here.

“We wanted to bring in industry experts to not only assess the quality of the proposals but also to attract industry support of the projects,” assistant vice president for intellectual property and industrial engagement at UH Michael Harold said in a news release. “It’s a win-win —reviewers get a first look at cutting-edge ideas, and the projects have a chance to build industry interest for future development.”

------

This article originally ran on EnergyCapital.

UH has named a new C-level exec to its Energy Transition Institute and entered into a new offshore partnership. Photo via UH.edu

University of Houston names new executive, partnership amid energy transition

go coogs

The University of Houston has made two big moves in growing its role in supporting the Houston energy transition.

UH to explore repurposing offshore tech for clean energy with new partnership

The two companies will work closely with UH's Repurposing Offshore Infrastructure for Clean Energy Project Collaborative, or the ROICE project. Photo via UH.edu

The University of Houston has signed a memorandum of understanding with two Houston-based companies that aims to repurpose offshore infrastructure for the energy transition.

The partnership with Promethean Energy and Endeavor Management ensures that the two companies will work closely with UH's Repurposing Offshore Infrastructure for Clean Energy Project Collaborative, or the ROICE project. The collaborative is supported by about 40 institutions to address the economic and technical challenges behind repurposing offshore wells, according to a statement from UH. It's funded in part by the Department of the Treasury through the State of Texas.

“These MOUs formalize our mutual commitment to advance the industry's implementation of energy transition strategies,” Ram Seetharam, Energy Center officer and ROICE program lead, said in the statement. “Together, we aim to create impactful solutions that will benefit both the energy sector and society as a whole.” Continue reading this story on EnergyCapital.

University of Houston names new energy transition-focused executive

Debalina Sengupta has been named as the chief operating officer of UH's Energy Transition Institute. Photo via UH.edu

The University of Houston has named a new C-level executive to its energy transition-focused initiative.

Debalina Sengupta has been named as the chief operating officer of UH's Energy Transition Institute, which was established in 2022 by a $10 million commitment from Shell USA Inc. and Shell Global Solutions (US) Inc. The institute focuses on hydrogen, carbon management and circular plastics and works closely with UH’s Hewlett Packard Enterprise Data Science Institute and researchers across the university.

Sengupta, who was previously a chemical engineer with over 18 years of experience with sustainability and resilience issues, was called to ETI’s mission and its focus on Houston, which is home to more than 4,500 energy companies and a pivotal international oil and gas hub.

“UH Energy Transition Institute is the first of its kind Institute setup in Texas that focuses solely on the transition of energy,” she says in a news release. “A two-way communication between the academic community and various stakeholders is necessary to implement the transition and I saw the UH ETI role enabling me to achieve this critical goal.” Continue reading this story on EnergyCapital.

------

These articles originally ran on EnergyCapital.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

UH med school gets $2M gift and more top Houston innovation news

Trending Topics

Editor's note: The top Houston innovation news of the month is full of fresh funding, with two Texas medical schools receiving major gifts — one of historic proportions. Below are the five most-read InnovationMap headlines from April 16-30, 2026.

UH med school granted $2M gift to offer student scholarships

A new scholarship endowment aims to support students in the University of Houston’s recently established medical school. The University of Houston’s Tilman J. Fertitta Family College of Medicine received a planned estate gift commitment estimated at $2.1 million to establish the Bob Diehl and Teresa Evans Diehl Scholarship Endowment. The scholarship will assist full-time medical students who demonstrate financial need and meet academic standards. Continue reading.

How Houston innovators played a role in the historic Artemis II splashdown

Research from Rice University played a critical role in the safe return of U.S. astronauts aboard NASA’s Artemis II mission this month. Rice mechanical engineer Tayfun E. Tezduyar and longtime collaborator Kenji Takizawa developed a key computational parachute fluid-structure interaction (FSI) analysis system that proved vital in NASA’s Orion capsule’s descent into the Pacific Ocean. The FSI system, originally developed in 2013 alongside NASA Johnson Space Center, was critical in Orion’s three-parachute design, which slowed the capsule as it returned to Earth, according to Rice. Continue reading.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March. Dr. Ryan S. Dhindsa hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation. Continue reading.

New UT Austin med center, anchored by MD Anderson, gets historic gift

A donation announced April 21 breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release. Continue reading.

Houston VC funding surged nearly 50% in Q1 2026, report says

Houston saw a jump in VC funding in Q1 2026, fueled by several major investments in clean energy startups. Image via Getty Images

First-quarter venture capital funding for Houston-area startups climbed nearly 50 percent compared to the same time last year, according to the PitchBook-NVCA Venture Monitor. In Q1 2026, Houston-area startups raised $532.3 million, a 49 percent jump from $320.2 million in Q1 2025, according to the PitchBook-NVCA Venture Monitor. However, the Q1 total fell 23 percent from the $671.05 million raised in Q4 2025. Continue reading.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”

View All Listings